The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II study comparing nivolumab (NIVO) with carboplatin-pemetrexed (CbPEM) for patients (pts) with EGFR mutation-positive non-small cell lung cancer (NSCLC) who acquire resistance to tyrosine kinase inhibitors (TKIs) not due to a secondary T790M mutation (WJOG8515L).
 
Hidetoshi Hayashi
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Merck Serono; Pfizer; Shanghai HaiHe Pharmaceutical
Research Funding - Abbvie (Inst); AC Medical (Inst); Astellas Pharma (Inst); AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Associates Co., Ltd. (Inst); GlaxoSmithKline (Inst); Japan Clinical Research Operations (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical; Otsuka (Inst); PAREXEL (Inst); Pfizer (Inst); PPD-SNBL (Inst); Quintiles Inc. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
Patents, Royalties, Other Intellectual Property - Sysmex
 
Shunichi Sugawara
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyowa Kirin; Lilly; MSD K.K; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Yakult Honsha
 
Yasushi Fukuda
No Relationships to Disclose
 
Yuki Sato
Honoraria - AstraZeneca; Chugai Pharma; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
 
Satoru Miura
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly; MSD
Speakers' Bureau - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Keiichi Ota
No Relationships to Disclose
 
Yuichi Ozawa
Honoraria - AstraZeneca; Chugai Pharma; MSD; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma
 
Satoshi Hara
No Relationships to Disclose
 
Junko Tanizaki
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly Japan; MSD; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca Japan
 
Koichi Azuma
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; MSD Oncology; Ono Pharmaceutical
 
Shota Omori
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo; MSD K.K; Novartis; Ono Pharmaceutical
 
Motoko Tachihara
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; MSD; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca (Inst)
 
Kazumi Nishino
Honoraria - AstraZeneca Japan; Chugai Pharma; Lilly Japan; Merck; Nippon Boehringer Ingelheim; Novartis; Pfizer; Roche
Research Funding - Nippon Boehringer Ingelheim
 
Shinobu Hosokawa
No Relationships to Disclose
 
Yasutaka Chiba
Honoraria - Chugai Pharma
 
Koji Haratani
Honoraria - AS ONE; AstraZeneca Japan
Speakers' Bureau - AstraZeneca Japan; Bristol-Myers Squibb; Chugai Pharma; MSD K.K; Ono Pharmaceutical
Research Funding - AstraZeneca Japan; MSD K.K
 
Kazuko Sakai
Honoraria - AstraZeneca; Bio-Rad; Chugai Pharma; Roche
 
Kazuto Nishio
Speakers' Bureau - Amgen; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Eisai; Guardant Health; Lilly Japan; Merck; MSD K.K.; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Roche; Sanofi; Solasia Pharma; SymBio Pharmaceuticals
Research Funding - Ignyta; Nippon Boehringer Ingelheim; North East Japan Study Group; Otsuka; Thoracic Oncology Research Group
 
Nobuyuki Yamamoto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Life Technologies; Lilly Japan; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyorin (Inst); Lilly (Inst); Maruho (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TERUMO (Inst); Toppan Printing Co. (Inst); Tosoh Corporation (Inst); Tsumura & Co. (Inst)
 
Kazuhiko Nakagawa
Honoraria - 3H Clinical Trial; Abbvie; Amgen; Amgen; AstraZeneca Japan; Bayer Yakuhin; Bristol-Myers Squibb; CareNet; Chugai Pharma; Kyorin; Kyowa Kirin Co., Ltd.; Lilly; Medical Mobile Communications; Medical Review Co., Ltd.; Merck; MSD K.K; Nikkei Business Publications, Inc; Nippon Boehringer Ingelheim; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Roche; Taiho Pharmaceutical; Takeda; YODOSHA
Consulting or Advisory Role - Kyorin; Lilly Japan; Ono Pharmaceutical; Pfizer
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Covance (Inst); Covance (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Holdings (Inst); EPS International (Inst); GlaxoSmithKline K.K. (Inst); IQvia (Inst); Japan Clinical Research Operations (Inst); Kissei Pharmaceutical (Inst); Lilly (Inst); Medical Reserch Support (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD K.K (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); PAREXEL International Corp. (Inst); Pfizer (Inst); Pfizer (Inst); PPD-SNBL (Inst); PRA HEALTHSCIENCES (Inst); Sanofi (Inst); SymBio Pharmaceuticals (Inst); Syneos Health (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)